Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, 23 August 2024 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2) is pleased to announce the publication of two new research reports by sponsored analysts, which delve into the fundamentals of the company's innovative pipeline and proprietary ExpreS2 platform.
The reports, authored by Analysguiden and Pareto Securities, provide detailed analyses of ExpreS2ion's lead asset, ES2B-C001, and the broader development pipeline.
Key Highlights:Analysguiden Report: Titled "At the Gates of Phase I," this report emphasizes the outlook for ES2B-C001 as it approaches Phase I clinical trials. Read the full report. (https://investor.expres2ionbio.com/wp-content/uploads/2024/08/2024-08-22-Analysguiden-At-the-gates-of-Phase-I.pdf)
Pareto Securities Report: This report provides a brief review of ExpreS2ion's Q2 2024 financial results. Read the full report. (https://investor.expres2ionbio.com/wp-content/uploads/2024/08/2024-08-15-Pareto-Q2-2024-financial-results.pdf)
Both reports highlight the transformative potential of the ExpreS2 platform for development of novel and improved vaccines and therapeutics for infectious diseases and cancer.
For more detailed insights and additional research reports, please visit the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of our investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB